| 000 | 01832 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515162010.0 | ||
| 264 | 0 | _c20090520 | |
| 008 | 200905s 0 0 eng d | ||
| 022 | _a0891-3668 | ||
| 024 | 7 |
_a10.1097/INF.0b013e3181903ed3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFarquhar, Carey | |
| 245 | 0 | 0 |
_aImmune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination. _h[electronic resource] |
| 260 |
_bThe Pediatric infectious disease journal _cApr 2009 |
||
| 300 |
_a295-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Bacterial _xblood |
| 650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aData Interpretation, Statistical |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization, Secondary |
| 650 | 0 | 4 |
_aImmunoglobulin G _xblood |
| 650 | 0 | 4 | _aKenya |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMeasles Vaccine _xadministration & dosage |
| 650 | 0 | 4 |
_aTetanus Toxoid _xadministration & dosage |
| 700 | 1 | _aWamalwa, Dalton | |
| 700 | 1 | _aSelig, Sara | |
| 700 | 1 | _aJohn-Stewart, Grace | |
| 700 | 1 | _aMabuka, Jennifer | |
| 700 | 1 | _aMajiwa, Maxwel | |
| 700 | 1 | _aSutton, William | |
| 700 | 1 | _aHaigwood, Nancy | |
| 700 | 1 | _aWariua, Grace | |
| 700 | 1 | _aLohman-Payne, Barbara | |
| 773 | 0 |
_tThe Pediatric infectious disease journal _gvol. 28 _gno. 4 _gp. 295-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/INF.0b013e3181903ed3 _zAvailable from publisher's website |
| 999 |
_c18699725 _d18699725 |
||